Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Nancy D. Doolittle; Lauren E. Abrey; Nicolay Ferrari; Walter A. Hall; Edward R. Laws; Roger E. McLendon; Leslie L. Muldoon; David Peereboom; Darryl R. Peterson; C. Patrick Reynolds; Peter Senter; Edward A. Neuwelt

Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Nancy D. Doolittle, Lauren E. Abrey, Nicolay Ferrari, Walter A. Hall, Edward R. Laws, Roger E. McLendon, Leslie L. Muldoon, David Peereboom, Darryl R. Peterson, C. Patrick Reynolds, Peter Senter, Edward A. Neuwelt

Neurology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

Original language	English (US)
Pages (from-to)	1702-1709
Number of pages	8
Journal	Clinical Cancer Research
Volume	8
Issue number	6
State	Published - 2002

ASJC Scopus subject areas

General Medicine

Cite this

Doolittle, N. D., Abrey, L. E., Ferrari, N., Hall, W. A., Laws, E. R., McLendon, R. E., Muldoon, L. L., Peereboom, D., Peterson, D. R., Reynolds, C. P., Senter, P., & Neuwelt, E. A. (2002). Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium. Clinical Cancer Research, 8(6), 1702-1709.

@article{a0c9571397ec47a685e4311aa98484e2,

title = "Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium",

abstract = "The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.",

author = "Doolittle, {Nancy D.} and Abrey, {Lauren E.} and Nicolay Ferrari and Hall, {Walter A.} and Laws, {Edward R.} and McLendon, {Roger E.} and Muldoon, {Leslie L.} and David Peereboom and Peterson, {Darryl R.} and Reynolds, {C. Patrick} and Peter Senter and Neuwelt, {Edward A.}",

year = "2002",

language = "English (US)",

volume = "8",

pages = "1702--1709",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Targeted delivery in primary and metastatic brain tumors

T2 - Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

AU - Doolittle, Nancy D.

AU - Abrey, Lauren E.

AU - Ferrari, Nicolay

AU - Hall, Walter A.

AU - Laws, Edward R.

AU - McLendon, Roger E.

AU - Muldoon, Leslie L.

AU - Peereboom, David

AU - Peterson, Darryl R.

AU - Reynolds, C. Patrick

AU - Senter, Peter

AU - Neuwelt, Edward A.

PY - 2002

Y1 - 2002

N2 - The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

AB - The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

UR - http://www.scopus.com/inward/record.url?scp=0036278836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036278836&partnerID=8YFLogxK

M3 - Article

C2 - 12060607

AN - SCOPUS:0036278836

SN - 1078-0432

VL - 8

SP - 1702

EP - 1709

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -

Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this